Liminal BioSciences — Investor Presentation (September 2022)
19 slides from Liminal BioSciences's investor presentation, Sep 13, 2022
Slide 1: Corporate Presentation September 2022
Aiming to develop Best/First-In-Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Corporate Presentation NASDAQ: LMNL September 2022
Slide 2: Safe Harbour
Safe Harbour This presentation contains forward-looking statements about Liminal BioSciences’ objectives, strategies and businesses that involve risks and uncertainties. Forward‐looking information includes statements concerning, among other things, the Company’s ability to regain compliance with th
Slide 3: Liminal Introduction
Aiming to develop Best/First In Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Liminal Introduction Pipeline is positioned to deliver multiple value catalysts in 2022/23 Intellectual Property (IP) all under the control of Liminal Progressing Diverse Pipelin
Slide 4: Management Team
LMNL is led by a strong, experienced team with proven track records in the discovery, development, and approval of biopharmaceuticals, all driven to make a difference. Management Team Bruce Pritchard Chief Executive Officer Executive Finance Positions: Prometic Life Sciences Inc., CV Therapeutics In
Slide 5: Opportunity to expand pipeline from in-house discovery engine
Opportunity to expand pipeline to study additional diversified candidates from the in-house discovery engine (over 3,000 compounds already generated). In-House Drug Discovery Engine Potential for in-house compounds to be augmented by in-licensed compounds. In-Licensed Compounds Potential access to n
Slide 6: Value creation strategy for best or first in class drug discovery
At Liminal, we are focused on elucidating compelling biological mechanisms and plan to advance a pipeline of small molecule therapeutics with best/first-in-class potential across a range of clinical indications with significant commercial prospects Compelling Biological Mechanisms Data-Driven. Dedic
Slide 7: 2022 Completed Milestones
2022 Completed Milestones Initiate Phase 1a Single-Ascending Dose (“SAD") clinical trial in fezagepras by H2 2022 in line with previous guidance Complete Phase 1a SAD clinical trial in fezagepras by Q3 2022 in line with previous guidance Update market on outcome of the Phase 1a SAD study by Q3 2022
Slide 8: Our Pipeline
Our Pipeline 8
Slide 9: GPR84: Role in Inflammation and Fibrosis
GPR84: Role in Inflammation and Fibrosis ROS = Reactive oxygen species = GPR84 = agonist Neutrophil Monocyte/Macrophage Pro-inflammatory/ Pro-fibrotic Activity GPR84 Agonists Pro-inflammatory cytokines Oxidative burst / ROS Chemotaxis Inflammatory conditions increase GPR84 expression
Slide 10: The GPR84 Receptor
The GPR84 Receptor 1. Wellen and Hotamisligil, 2005 2. Libby, Ridker and Hansson, 2011 3. Puengel et al., 2020 4. Wojciechowicz and Ma’ayan 2020 What is the GPR84 Receptor? The GPR84 receptor is primarily expressed in immune cells in addition to multiple organ systems. It plays a key role in the lin
Slide 11: GPR84 Expected Milestones
GPR84 Expected Milestones Commence IND/CTA enabling studies for regulatory approval of clinical trial Regulatory Submission for Phase 1 Clinical Trial H1 2023 Commence first-in-human clinical trial 2022 Preclinical candidate selection and guidance on potential target disease areas H2 2023
Slide 12: OXER1 Antagonist
— OXER1 Antagonist ‘© 2022 Liminal BioSciences tne.
Slide 13: OXER1: Role in Tissue Repair and Inflammation
OXER1: Role in Tissue Repair and Inflammation 1. Gail et al, 2009 What is the OXER1 Receptor? OXER1 is a GPCR receptor which is mainly expressed in inflammatory cells. OXER1 is highly selective for 5-oxo-ETE, one of the most powerful chemo-attractants and activators of eosinophils. Why are eosinophi
Slide 14: OXER1 Potential To Treat Eosinophilic-Driven Disease
OXER1 Potential To Treat Eosinophilic-Driven Disease Gastrointestinal Diseases Respiratory Diseases Other Diseases Skin Diseases Eosinophils are involved in acute and chronic inflammation and play an important role in a large number of allergic, inflammatory and proliferative diseases. Both eosinoph
Slide 15: Development Rationale & Opportunities in Eosinophil-related Diseases
Development Rationale & Opportunities in Eosinophil-related Diseases There are many drug development approaches to limit eosinophil-related tissue damage Eosinophil-targeting biology proven with existing, approved, monoclonal antibody drugs Reducing eosinophil levels shown to improve outcomes in sev
Slide 16: OXER1 Expected Milestones
OXER1 Expected Milestones Commence IND/CTA enabling studies for regulatory approval of clinical trial Regulatory Submission for Phase 1 clinical Trial H1 2024 Commence first-in-human clinical trial H2 2023 Preclinical candidate selection and guidance on potential target disease areas H2 2024
Slide 17: Expected Program Milestones
Data Driven Execution and Delivery Expected Program Milestones GPR84 Antagonist Program 2022: Pre-clinical candidate selection and guidance on potential target disease areas 2022: Commence IND/CTA enabling studies for regulatory approval of clinical trial 2023: Regulatory submission for Phase 1 clin
Slide 18: Expected Organisational Milestones
Data Driven Execution and Delivery Expected Organisational Milestones Drug Discovery Platform 2022/2023: Opportunity to expand pipeline to study additional candidates with novel targets and novel pathways from in-house discovery engine 2022/2023: Seek opportunities for potential acquisition of clini
Slide 19: Executive Summary
All figures presented in this section are in Canadian dollars unless otherwise specified. Executive Summary Cash as of June 30, 2022 $55.8M Potential development opportunities from in-house drug discovery platform Ongoing opportunity to monetise non-core assets Access to NASDAQ Market: LMNL Debt fre
Liminal BioSciences — Investor Presentation (September 2022) on 6ix